drugset / Trial / NCT00281515

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

NCT00281515

Phase 2 Completed 105 enrolled AGO Study Group
RandomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian cancer.

Timeline

Start
2006-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lonafarnib Small molecule 200 mg Oral